Aligos Therapeutics opened higher at $2.21, compared with its previous close of $2.16. In the last trading session, the stock traded between $1.92 and $2.32. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Aligos Therapeutics is now worth
$ 0.47
Resulting in a loss of
$ 99.53 (99.53%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.18 (-8.33%)
Day High
$2.32
Day Low
$1.92
Day Open
$2.21
Prev Close
$2.16
Volume
1,17,294
1W Return
-61.10%
1M Return
-64.29%
3M Return
-72.79%
6M Return
-68.12%
1Y Return
-70.36%
Fundamentals
Market Cap ($ Mn)
11
PE Ratio
-
PB Ratio
1.35
PEG Ratio
-
ROE
-38.44%
ROCE
-30.92%
EPS (TTM)
$-3.50
Investment Returns
1 Week
-61.10%
1 Month
-64.29%
3 Months
-72.79%
6 Months
-68.12%
9 Months
-73.46%
Financials
Quarterly
All values in $ Mn
0.3
Mar 25
1.0
Jun 25
0.7
Sep 25
0.2
Dec 25
27.8
Jun 26
2.9
Sep 26
Updates
6Nov
Aligos Therapeutics Q3FY26 Results: Net loss narrows 30% YoY to $21.9 million
Net loss narrowed 30% YoY to $21.9 million driven by lower R&D expenses. EPS of $(2.09) beat consensus estimate of $(2.28) by 8.33%. Revenue of $2.83 million missed analyst estimate of $5.543 million by 48.94%. Cash position dropped to $31.1 million, providing runway only into Q1 2027.
6 days ago
6Oct
Aligos Therapeutics to present five abstracts at AASLD Liver Meeting 2026
Aligos Therapeutics accepted five abstracts for The Liver Meeting 2026. Pevifoscorvir sodium data shows HBsAg reduction to < 3,000 IU/mL. ALG-170675 ASO demonstrates efficacy in AAV-HBV mouse models. Conference scheduled for November 5 to 9, 2026, in Denver.
1mo ago
13Aug
Aligos Therapeutics initiates Phase 1 dosing for HBV drug ALG-170675
Aligos Therapeutics has commenced Phase 1 dosing for ALG-170675, a next-generation ASO for chronic HBV, through its partner Amoytop in China. The trial involves single and multiple ascending doses in healthy volunteers, with patient enrollment planned for Q4 2026. The drug features novel monomers aimed at reducing toxicity and improving liver-to-kidney ratios compared to existing therapies.
Aligos Therapeutics Inc. announced the completion of enrollment for HBeAg+ and HBeAg- participants in the Phase 2 B-SUPREME trial of pevifoscorvir sodium. The study enrolled 131 and 114 participants respectively, with topline data anticipated in late Q3 2027. This progress builds on a previous $25M license deal with Xiamen Amoytop Biotech for Greater China rights.
